Elevated Levels of Cerebrospinal Fluid and Plasma Interleukin-37 in Patients with Guillain-Barré Syndrome

Table 1

The demographic and clinical characteristics of subjects.

Parameters	Healthy controls	GBS patients
Number	20	25
Age (years)	32 (16–63)	39 (14–56)
Gender (F/M)	8/12	10/15
WBC in CSF (10^6/L)	0.54 (0.17–1.0)	0.72 (0.21–1.0)
Albumin in CSF (g/L)	0.24 (0.16–0.39)	0.65 (0.49–2.05)*
Albumin in plasma (g/L)	40.53 (35.2–50.67)	42.1 (30.24–53.1)
Qalb × 100	0.59 (0.32–1.11)	1.54 (0.92–6.78)*
Treatment	NA	IV immunoglobulin
WBC (×10^9/L)	6.7 (4.2–9.3)	8.55 (4.5–26)*
Lymphocytes (×10^9/L)	2.43 (0.81–3.66)	3.79 (0.94–5.2)
Outcome
Drug responders	NA	16
Drug nonresponders	NA	9

Data shown are median (range) of each group of subjects. WBC: white blood cells; Qalb: albumin in CSF versus albumin in plasma. (A): acute phase; ^∗𝑃<0.05 versus the HC.